Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China

Patients

The study was approved by the Ethics Committee of Guangzhou Eighth People’s Hospital. Thirty-one individuals who were diagnosed to have mild/moderate COVID-19 symptoms (17 men, 14 women, average age=44.5), and 25 individuals who were diagnosed to show severe COVID-19 symptoms (18 males, 7 females, average age=66) in Guangzhou Eighth People’s Hospital between January 2020 and February 2020 were enrolled in the study with informed consent. Diagnosis of COVID-19 infection, pneumonia and clinical classification was based on the new coronavirus pneumonia diagnosis and treatment plan (trial version 6) issued by the National Health Committee of the People’s Republic of China. The clinical classifications are on the basis of the following manifestations: (1) mild/moderate: fever, respiratory tract symptoms, and pneumonia on chest CT scan. Respiratory rate > 30 beats/min, or mean oxygen saturation < 93% (2) severe: one of the following: respiratory distress with respiratory rate > 30 beats/min, peripheral capillary oxygen saturation ≤ 93%, the ratio of partial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2) < 300, respiratory failure requiring mechanical ventilation, Shock, ICU admission required for combined organ failure, pulmonary pathological progression. All patients were confirmed by the test on upper respiratory throat swab samples using the standard COVID-19 test kit. Individuals with fever and negative for the SARS-CoV-2 test were recruited as controls.

Sample collection

Two to four milliliters of peripheral venous blood was withdrawn from each patient into K3 EDTA blood collection tubes. The complete blood cell count was performed on an XN-A1 automatic blood analyzer (Sysmex). The reagents, calibrators, and quality controls were from the same vendor.

Flow cytometry assay

To analyze serum cytokines, the whole blood was centrifuged at 500×g for 5 minutes at 4°C. The serum was carefully harvested and stored at −80°C before analysis. Multiple serum cytokines were quantified using the Human Th1/Th2 Cytokine Kit II (Guangzhou Weimi Bio-Tech) following the manufacturer’s manual.

To measure lymphocytes and T cell subsets, 100 µl of whole blood was incubated in 900 µl of Tris-NH₄Cl buffer (Thermo Fisher Scientific) at room temperature for 5 minutes to lyse erythrocytes. After two washes with phosphate-buffered saline (PBS), cells were incubated with BD Multitest 6-Color TBNK Reagent or BD Multitest CD3/CD8/CD45/CD4 (BD Biosciences) following the vendor’s instructions. After another two washes with PBS, cells were resuspended in 500 µl of PBS

To evaluate regulatory T cells, erythrocytes were lysed as described above. The blood samples were then incubated with FITC-conjugated CD4 antibody, Violet 450-conjugated CD127 antibody, Percp-conjugated CD45 antibody, and APC-conjugated CD25 antibody (5µg/ml each, all from BD Biosciences) for 15 minutes on ice. After another two washes with PBS, cells were resuspended in 500 µl of PBS.

Samples were analyzed on a BD FACSCanto Plus flow cytometer. Among all collected events, single events were gated between FSC-A and FSC-H. Cell debris was excluded and intact cells were then gated from single events based on FSC-A and SSC. Each cell population was then detected based on the antibody staining.

Statistics

The data were indicated as mean□±□standard deviation and measured by GraphPad Prism 6.0. Non parametric Kruskal-Wallis test or One-way ANOVA with post-hoc Tukey HSD test was applied to compare the mean values or mean ranks among different groups, depending on the presence or absence of Gaussian distribution.

T cell cellularity is reduced in COVID-19 patients

To assess the general immune status of COVID-19 patients, we first quantified the absolute number of whole white blood cells (WBC) and immune cell populations in blood samples of patients at inpatient admission. As indicated in Figure 1A, WBC number was significantly decreased in mild patients as compared with the control group. However, WBC number was not remarkably changed in severe patients. Total lymphocyte number was decreased in severe patients but not in mild patients, suggesting the lymphopenia severe patients (Figure 1B). Neutrophils were increased in severe patients but not in mild patients (Figure 1C). The neutrophil-to-lymphocyte ratio (NLR), consistent with the change in lymphocytes, was moderately increased in mild patients and profoundly increased in severe patients, in comparison to the control group (Figure 1D). To analyze the adaptive immune cell populations, we conducted flow cytometry analysis on CD45+CD3+ total T cells, CD3+CD4+ T helper cells and CD3+CD8+ cytotoxic T cells (Figure 1E). We found a similar decrease in CD45+ lymphocytes in COVID-19 patients (Figure 1F). Total T cell number was significantly decreased in COVID-19 patients, but no significant difference was observed between mild and severe patients (Figure 1G). Similarly, CD4+ T helper cells and CD8+ cytotoxic T cells were diminished in COVID-19 patients as compared with the control group, but no significant difference was found between mild and severe patients (Figure 1H & 1I). The ratio between CD4+ T cells and CD8+ T cells was not changed (Figure 1J).

• Download figure
• Open in new tab

Figure 1. Cellularity of blood T cells in COVID-19 patients at hospital admission.

(A to C) Absolute cell number of white blood cells (WBC), lymphocytes (LYM), and neutrophils. (D) Neutrophil-to-Lymphocyte ratios. (E) Representative flow cytometry dot plots showing the gating strategy for total T cells, CD4+ T cells, and CD8+ T cells. C: control; M: mild; S: severe. (F to I) Quantification of the number of CD45+ lymphocytes, total T cells, CD4+ T cells, and CD8+ T cells using flow cytometry analysis. (J) Ratio between CD4+ T cells and CD8+ T cells. *, p<0.05; **, p<0.01; ***, p<0.001.

B cells and NK cells are decreased in COVID-19 patients

Other immune cells including CD3-CD19+ B cells, CD3-CD16+CD56+ NK cells and CD3+CD16+CD56+ NKT cells were also evaluated in blood samples (Figure 2A). We found that in comparison with the control group, there was a trend of decrease in B cell cellularity in mild COVID-19 patients, and a notable reduction in B cells of severe COVID-19 patients (Figure 2B). A similar decrease was also seen in COVID-19 patients’ NK cells (Figure 2C). No remarkable change in NKT cellularity was observed in COVID-19 patients (Figure 2D).

• Download figure
• Open in new tab

Figure 2. Cellularity of blood B cells, NK cells and NKT cells in COVID-19 patients at hospital admission.

(A) Representative flow cytometry dot plots showing the gating strategy for B cells, NK cells and NKT cells. (B to D) Quantification of the number of B cells (B), NK cells (C) and NKT cells (D). *, p<0.05; **, p<0.01.

Regulatory T cells (Tregs) are increased in mild COVID-19 patients

Tregs are an important T cell subset for immune tolerance and anti-inflammatory reaction. In our study, we measured the cellularity of CD3+CD4+CD25+CD127-T cells which were considered a Treg-enriched population (Figure 3A). We found that Tregs were increased in mild COVID-19 patients as compared with controls (Figure 3B). There was only a slight increase in Tregs in severe patients (Figure 3B).

• Download figure
• Open in new tab

Figure 3. Cellularity of blood Tregs in COVID-19 patients at hospital admission.

(A) Representative flow cytometry dot plots showing the gating strategy for Tregs. (B) Quantification of the number of Tregs. **, p<0.01.

IL-2, IL-10, and IL-6 reflect the severity of COVID-19

Cytokines are crucial biomarkers of the progression of various inflammatory disorders including pneumonia. We characterized the expression of Th1 cytokine (IL-2 & IFN-γ), Th2 cytokines (IL-4 & IL-10), and pro-inflammatory cytokines (IL-6 & TNF-α) in the blood samples of patients at inpatient admission (Figure 4A). As demonstrated in Figure 4B, as compared with controls, IL-2 was considerably increased in severe patients but not in mild patients. IL-4 was remarkably raised in mild patients but not in severe patients (Figure 4C). IL-6 was significantly increased in severe patients but not in mild patients (Figure 4D). Like IL-2 and IL-6, IL-10 and TNF-α were significantly increased in severe patients but not in mild patients (Figure 4E & 4F). IFN-γ, however, showed no significant change in COVID-19 patients (Figure 4G).

• Download figure
• Open in new tab

Figure 4. Cytokine levels in COVID-19 patients.

(A) Representative flow cytometry dot plots showing the cytokine expression in patients. (B to G) Expression of indicated cytokines in COVID-19 patients at hospital admission. **, p<0.01; ***, p<0.001. (H to M) Expression of indicated cytokines in COVID-19 patients relative to the length of hospital stay. *, p<0.05; ***, p<0.001 in comparison to “Mild” of the same time interval. #, p<0.05; ###, p<0.001 in comparison to the corresponding “Severe 1-5” group.

We also evaluated the cytokine concentrations relative to the length of stay hospital. We found that severe patients always had a higher IL-2 level than mild patients in the same time intervals, and IL-2 reached a peak in severe patients on day 15-20, followed by a moderate decline. IL-2 was not significantly changed in mild patients along the stay (Figure 4H). No dramatic temporal change of IL-4 was observed in either mild patients or severe patients (Figure 4I). The IL-6 level in mild patients was always very low, while IL-6 was drastically increased in severe patients. Interestingly, as IL-2, IL-6 stayed at a relatively stable levels within two weeks, and then went up on day 15-20 followed by a decline back to the initial level (Figure 4J). IL-10, too, was always higher in severe patients than mild patients. Besides, IL-10 in severe patients underwent a further up-regulation on day 5-10 and day 10-15, respectively (Figure 4K). The changes in the levels of TNF-α and IFN-γ were almost neglectable (Figure 4L & 4M), suggesting that they probably are not good indicators of COVID-19 severity.